Frequent launch of new cough suppressants in the market by key players is expected to drive the cough suppressant market growth over the forecast period. For instance, in March 2018, Perrigo Company plc. received the FDA approval for the brand OTC equivalent of Mucinex DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-release Tablets, 1200 mg/60 mg). Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive.
Various key players in the market are conducting research and are evaluating safety and efficacy of various for the treatment of cough. Such initiatives taken by companies is expected to lead to the development of new cough suppressant .
For instance, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is evaluating the efficacy and safety of benzonatate soft capsules for improving adult cough symptoms, wherein the study is currently (2018) under phase 3 clinical trial.
Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/2427
Moreover, high prevalence of cough is expected to increase the demand for cough suppressant , thereby driving the market growth. For instance, according to the study published by the National Center for Biotechnology Information in 2013, cough is a very common condition and around 12% of the people in Britain experience chronic cough, daily or weekly.
For instance, in February 2018, the Therapeutic Goods Administration reclassified codeine as prescription only medicine in Australia, which was previously available as over-the-counter. This reclassification was made, as regular use of medicines containing codeine may lead to its addiction.
In January 2018, the U.S. Food and Drug Administration made safety labeling changes to limit the use of codeine or hydrocodone containing prescription opioid cough and cold medicines in children younger than 18 years old to protect kids from serious risks of opioid ingredients containing cough treatment. After the safety labeling changes, these products will no longer be indicated for treatment of cough in pediatric population and will be labeled for use only in adults aged 18 years and older.
Key players operating in the global cough suppressant market include Perrigo Company plc, Vernalis plc, Tris Pharma Inc., Pfizer Inc., Aytu BioScience, Inc., Acella Pharmaceuticals LLC, Mayne Pharma Inc., Taro Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd, and GlaxoSmithKline plc.
The research report on Cough Suppressant Drugs Market evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The report extensively provides the market share, growth, trends and forecasts for the period 2018-2026. The market size in terms of revenue (USD MN) is calculated for the study period along with the details of the factors affecting the market growth (drivers and restraints).
The comprehensive value chain analysis of the market will assist in attaining better product differentiation, along with detailed understanding of the core competency of each activity involved. The market attractiveness analysis provided in the report aptly measures the potential value of the market providing business strategists with the latest growth opportunities. The report classifies the market into different segments based on technique, application and end-user. These segments are studied in detail incorporating the market estimates and forecasts at regional and country level. The segment analysis is useful in understanding the growth areas and probable opportunities of the market.
Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2427